AstraZeneca's COVID-19 Antibody Cuts Risk Of Symptomatic Disease By 77%

A new coronavirus antibody treatment developed by AstraZeneca plc AZN reduced the risk of developing the symptomatic disease by 77% compared to placebo.
Related: AstraZeneca's AZD7442 did not meet the primary endpoint of post-exposure prevention of symptomatic COVID-19.
The trial included around 5,000 participants who did not have SARS-CoV-2 infection at baseline.
More than 75% of participants had co-morbidities, which include conditions that have been reported to cause a reduced immune response to vaccination.
The results of the Provent phase III pre-exposure prophylaxis trial showed there were no cases of severe COVID or COVID-related deaths in those treated with the "antibody cocktail" AZD7442.
The trial accrued 25 cases of symptomatic COVID-19 at the primary analysis.
In the placebo arm, there were three cases of severe COVID-19, which included two deaths.
AstraZeneca said that the antibody combination, delivered through an injection to the muscle, could give people up to 12 months of protection from COVID-19.
See: UK Approves Regeneron - Roche's COVID-19 Antibody Cocktail
It is the first non-vaccine antibody combination modified to provide potentially long-lasting protection that has demonstrated prevention of COVID-19 in a clinical trial, AstraZeneca added.
AstraZeneca is now preparing the regulatory submission of the prophylaxis data to health authorities for potential emergency use authorization or conditional approval of AZD7442.
Price Action: AZN shares are up 0.52% at $59.49 during the market session on the last check Friday.

Market News and Data brought to you by Benzinga APIs

Comments

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga